Hello!
Hallo!
Bonjour!
Ciao!
Hallå!
Hej!
Hola!
Hello!

How we can help

Preparation 

European Landscape Assessment

HTA Decision Analysis

Payer research and advisory boards

Joint/Parallel Scientific Advice

Key Country Market Insights

Belgium

France

Germany

Italy

Netherlands

Nordics

Spain

Switzerland

UK

Strategy 

a

Market Access & Value Strategy

Value Story & Message Development

Evidence Gap Analysis

Evidence Generation Planning

Value-based Price Potential

Multi-national HTA strategy

Execution 

a

Country HTA Submissions

European Launch Management

Questions we answer

Is it worth launching your latest asset in Europe?
US & global biotechs come to AESARA Europe for expert, evidence-based, go/no-go market access advice.
What should you invest in Europe – and when?
US & global biotechs hire AESARA Europe for asset due diligence, value-based pricing and European market access infrastructure build.
Will European payers value your medical innovation?
US & global biotechs use AESARA’s European market access industry-veterans to optimise their value evidence and product value propositions for European health technology assessments.
How should you best structure and sequence your European HTA submissions for strategic impact and operational efficiency?
US and global biotechs use AESARA's European and in-country experts to plan and execute successful HTA, pricing and reimbursement submissions
What value evidence will European HTA bodies need to see in support of your value story, target population & price?
Global biotech and pharma companies trust AESARA Europe's insight and experience to test and optimise value propositions and value evidence plans, for European HTA and reimbursement success

Strategy leaders

Gavin J. Outteridge, MA (Oxon) 

is the Managing Director of Europe for AESARA. Gavin delivers measurable business improvement for global life sciences clients through advising executives on value & access strategy, communications and organizational design.

With over 21 years of leadership experience, including 17 in life sciences, Gavin believes the life sciences sector is a social good and that a regulated market is the best way of delivering innovation and value. Consequently, he works with clients in Development and Commercialization functions to optimize how they demonstrate scientifically-sound cost-risk-benefit and, by doing so, deliver value to patients, to payers and to investors.

Prior to AESARA, Gavin was on the Executive Committee of life sciences services company Kinapse; held a change management role in Pfizer R&D; and began his working life as an officer in the Royal Air Force.

Catherine Chamoux, PhD

has international experience acquired over thirty+ years in the pharma industry in medium-sized and large companies. She holds a PhD in Pharmacy and a Masters of Public Health from Sciences Po, Paris. She is an expert in Market Access for innovative drugs.

As a member of the leadership team of the French affiliate of a leading US biotech for 15 years, she helped establish & develop the company locally, directly negotiated product prices & access conditions, developed relationships with regulators, payors and KOLs. She also actively participated in the evidence generation and early access program strategies for our innovative therapies, including orphan drug products, highlighting the unmet needs and the products’ unique attributes.

She also has strong pan-European experience in Market Access, having most recently led the Market Access Excellence function for Europe, creating common understanding, tools, measures and co-operation between countries.

Case studies

European Sequencing Strategy
European HTA Submission Programme
European Asset Due Diligence

Why AESARA?

Change Before Change

We are forward thinking and driven by the impact you need

Biopharma DNA

We have walked in your shoes and know what needs to get done

Partner with those that have walked in your shoes

Having both the big picture perspective and the methodological know-how, our strategic consultants come from industry and have molecule-to-launch experience in a complex and changing global healthcare landscape.

EUROPE OFFICE

CONVERSATIONS